The aim of our study is to investigate the effect of
sunitinib on
diabetes mellitus related-ovarian injury and
fibrosis in rat models. An
experimental diabetes mellitus model was created in 16 rats, and eight rats with normal
blood glucose levels were included in control group (Group-1). The diabetic rats were divided into two groups:diabetic control group (water given) - Group-2 and
sunitinib treatment group - Group-3. After four weeks, bilateral
oophorectomy was performed and ovaries were examined histologically. The groups were compared by Student's t-test, analysis of variance (ANOVA) and Mann-Whitney's U-test. There was a significant increase in no-medication (water given) diabetic rat's ovary (Group-2) in terms of follicular degeneration, stromal degeneration, stromal
fibrosis and
NF-kappaB immune-expression compared with control group normal rats' ovary (Group-1) (p < 0.0001). Stromal degeneration (p = 0.04), stromal
fibrosis (p = 0.01), follicular degeneration (p = 0.02),
NF-kappaB immune-expression (p = 0.001) significantly decreased in
sunitinib-treated diabetic rat's ovary (Group-3) when compared with no-medication (water given) diabetic rat's ovary (Group-2) (p < 0.05). When we used
sunitinib in the treatment of diabetic rats, ovarian injury,
fibrosis and
NF-kappaB immunoexpression decreased significantly. The effects of
sunitinib in rat models give hope to the improved treatment of
premature ovarian failure due to
diabetes mellitus in humans.